These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34593524)

  • 41. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
    Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
    Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
    Sasca D; Szybinski J; Schüler A; Shah V; Heidelberger J; Haehnel PS; Dolnik A; Kriege O; Fehr EM; Gebhardt WH; Reid G; Scholl C; Theobald M; Bullinger L; Beli P; Kindler T
    Blood; 2019 May; 133(21):2305-2319. PubMed ID: 30814062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting leukemia-specific dependence on the de novo purine synthesis pathway.
    Yamauchi T; Miyawaki K; Semba Y; Takahashi M; Izumi Y; Nogami J; Nakao F; Sugio T; Sasaki K; Pinello L; Bauer DE; Bamba T; Akashi K; Maeda T
    Leukemia; 2022 Feb; 36(2):383-393. PubMed ID: 34344987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.
    Karsten S; Fiskesund R; Zhang XM; Marttila P; Sanjiv K; Pham T; Rasti A; Bräutigam L; Almlöf I; Marcusson-Ståhl M; Sandman C; Platzack B; Harris RA; Kalderén C; Cederbrant K; Helleday T; Warpman Berglund U
    Cell Death Differ; 2022 Jan; 29(1):246-261. PubMed ID: 34453118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
    Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
    Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
    Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
    Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.
    Xiao Y; Zou P; Wang J; Song H; Zou J; Liu L
    J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):328-333. PubMed ID: 22684553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
    Drusbosky L; Gars E; Trujillo A; McGee C; Meacham A; Wise E; Scott EW; Cogle CR
    Leuk Res; 2015 Sep; 39(9):984-9. PubMed ID: 26189107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
    Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
    Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
    Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).
    Blair A; Sutherland HJ
    Exp Hematol; 2000 Jun; 28(6):660-71. PubMed ID: 10880752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.